| Inbound Relationships |
Type |
Active |
Source |
Characteristic |
Refinability |
Group |
| Tobramycin ophthalmic agent |
Is a |
False |
Tobramycin (substance) |
Inferred relationship |
Some |
|
| Tobramycin sulfate |
Is a |
False |
Tobramycin (substance) |
Inferred relationship |
Some |
|
| Tobramycin poisoning |
Causative agent (attribute) |
True |
Tobramycin (substance) |
Inferred relationship |
Some |
1 |
| Accidental tobramycin poisoning |
Causative agent (attribute) |
False |
Tobramycin (substance) |
Inferred relationship |
Some |
|
| Intentional tobramycin poisoning |
Causative agent (attribute) |
False |
Tobramycin (substance) |
Inferred relationship |
Some |
|
| intoxication par la tobramycine d'intention indéterminée |
Causative agent (attribute) |
False |
Tobramycin (substance) |
Inferred relationship |
Some |
1 |
| Tobramycin adverse reaction |
Causative agent (attribute) |
True |
Tobramycin (substance) |
Inferred relationship |
Some |
1 |
| Allergy to tobramycin |
Causative agent (attribute) |
False |
Tobramycin (substance) |
Inferred relationship |
Some |
|
| Tobramycin overdose |
Causative agent (attribute) |
True |
Tobramycin (substance) |
Inferred relationship |
Some |
1 |
| Accidental tobramycin overdose |
Causative agent (attribute) |
True |
Tobramycin (substance) |
Inferred relationship |
Some |
1 |
| Intentional tobramycin overdose |
Causative agent (attribute) |
True |
Tobramycin (substance) |
Inferred relationship |
Some |
1 |
| surdose de tobramycine d'intention indéterminée |
Causative agent (attribute) |
False |
Tobramycin (substance) |
Inferred relationship |
Some |
1 |
| Serum tobramycin measurement |
Component |
False |
Tobramycin (substance) |
Inferred relationship |
Some |
2 |
| Plasma tobramycin measurement |
Component |
False |
Tobramycin (substance) |
Inferred relationship |
Some |
2 |
| Tobramycin [respiratory use] |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Tobramycin (substance) |
Inferred relationship |
Some |
|
| Tobramycin 300mg/5mL nebulizer solution |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Tobramycin (substance) |
Inferred relationship |
Some |
|
| Tobramycin [systemic] |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Tobramycin (substance) |
Inferred relationship |
Some |
|
| tobramycine 10 mg/mL, ampoule de 2 mL de solution injectable |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Tobramycin (substance) |
Inferred relationship |
Some |
|
| tobramycine 40 mg/mL, ampoule de 1 mL de solution injectable |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Tobramycin (substance) |
Inferred relationship |
Some |
|
| tobramycine 40 mg/mL, ampoule de 2 mL de solution injectable |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Tobramycin (substance) |
Inferred relationship |
Some |
|
| Tobramycin [eye] |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Tobramycin (substance) |
Inferred relationship |
Some |
|
| Tobramycin 10mg/mL injection solution 1mL ampule |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Tobramycin (substance) |
Inferred relationship |
Some |
|
| Tobramycin 1.2g powder for injection solution vial |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Tobramycin (substance) |
Inferred relationship |
Some |
|
| Tobramycin 60mg/mL solution |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Tobramycin (substance) |
Inferred relationship |
Some |
|
| Tobramycin 3 mg/mL eye solution |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Tobramycin (substance) |
Inferred relationship |
Some |
|
| Tobramycin 3 mg/g eye ointment |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Tobramycin (substance) |
Inferred relationship |
Some |
|
| Dexamethasone + tobramycin 0.1%wv/0.3%wv suspension |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Tobramycin (substance) |
Inferred relationship |
Some |
|
| Dexamethasone + tobramycin 1mg/3mg ointment |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Tobramycin (substance) |
Inferred relationship |
Some |
|
| Tobramycin measurement |
Component |
True |
Tobramycin (substance) |
Inferred relationship |
Some |
1 |
| Tobramycin 240mg/6mL injection |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Tobramycin (substance) |
Inferred relationship |
Some |
|
| Product containing tobramycin in parenteral dose form (medicinal product form) |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
True |
Tobramycin (substance) |
Inferred relationship |
Some |
1 |
| Tobramycin 1.2mg/mL injection |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Tobramycin (substance) |
Inferred relationship |
Some |
|
| Tobramycin 1.6mg/mL injection |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Tobramycin (substance) |
Inferred relationship |
Some |
|
| Tobramycin 80mg/100mL infusion |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Tobramycin (substance) |
Inferred relationship |
Some |
|
| Product containing tobramycin (medicinal product) |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
True |
Tobramycin (substance) |
Inferred relationship |
Some |
1 |
| Dexamethasone 1 mg/mL and tobramycin 3 mg/mL eye drops |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Tobramycin (substance) |
Inferred relationship |
Some |
|
| Product containing dexamethasone and tobramycin (medicinal product) |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
True |
Tobramycin (substance) |
Inferred relationship |
Some |
2 |
| Tobramycin 240mg/6mL injection |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Tobramycin (substance) |
Inferred relationship |
Some |
|
| Product containing fluorometholone and tobramycin (medicinal product) |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
True |
Tobramycin (substance) |
Inferred relationship |
Some |
2 |
| Tobramycin 0.3%/fluorometholone 0.1% ophthalmic suspension |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Tobramycin (substance) |
Inferred relationship |
Some |
|
| Loteprednol etabonate + tobramycin |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Tobramycin (substance) |
Inferred relationship |
Some |
|
| Loteprednol etabonate 5 mg/mL and tobramycin 3 mg/mL eye suspension |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Tobramycin (substance) |
Inferred relationship |
Some |
|
| Accidental tobramycin poisoning |
Causative agent (attribute) |
True |
Tobramycin (substance) |
Inferred relationship |
Some |
1 |
| Intentional tobramycin poisoning |
Causative agent (attribute) |
True |
Tobramycin (substance) |
Inferred relationship |
Some |
1 |
| Product containing tobramycin in ophthalmic dosage form |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Tobramycin (substance) |
Inferred relationship |
Some |
|
| Product containing tobramycin in respiratory dosage form |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Tobramycin (substance) |
Inferred relationship |
Some |
|
| Measurement of tobramycin in random specimen (procedure) |
Component |
True |
Tobramycin (substance) |
Inferred relationship |
Some |
1 |
| Measurement of tobramycin peak concentration |
Component |
True |
Tobramycin (substance) |
Inferred relationship |
Some |
1 |
| Measurement of tobramycin trough concentration |
Component |
True |
Tobramycin (substance) |
Inferred relationship |
Some |
1 |
| Dexamethasone 500 microgram/mL and tobramycin 3 mg/mL eye suspension |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Tobramycin (substance) |
Inferred relationship |
Some |
|
| Allergy to tobramycin |
Causative agent (attribute) |
True |
Tobramycin (substance) |
Inferred relationship |
Some |
1 |
| Tobramycin desensitization therapy |
Using substance (attribute) |
True |
Tobramycin (substance) |
Inferred relationship |
Some |
2 |
| Tobramycin sulfate |
This attribute indicates that the concept is a structural modification of another concept, and that the substance's intrinsic physicochemical properties remain unchanged. |
True |
Tobramycin (substance) |
Inferred relationship |
Some |
|
| Product containing loteprednol and tobramycin (medicinal product) |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
True |
Tobramycin (substance) |
Inferred relationship |
Some |
1 |
| Dexamethasone 1 mg/mL and tobramycin 3 mg/mL eye drops |
This attribute represents an ingredient that is the part of the active ingredient that the strength of a given product is based upon. |
False |
Tobramycin (substance) |
Inferred relationship |
Some |
1 |
| Dexamethasone 1 mg/mL and tobramycin 3 mg/mL eye drops |
The most specific description of a substance present in the manufactured dose form, before any dilution or transformation. It includes modifiers, such as salts, esters, polymers (e.g. pegylation), and/or solvates (including waters of hydration). |
False |
Tobramycin (substance) |
Inferred relationship |
Some |
1 |
| Product containing precisely tobramycin (as tobramycin sulfate) 40 milligram/1 milliliter conventional release solution for injection ampule |
This attribute represents an ingredient that is the part of the active ingredient that the strength of a given product is based upon. |
False |
Tobramycin (substance) |
Inferred relationship |
Some |
1 |
| Product containing precisely tobramycin (as tobramycin sulfate) 80 milligram/2 milliliter conventional release solution for injection ampule |
This attribute represents an ingredient that is the part of the active ingredient that the strength of a given product is based upon. |
False |
Tobramycin (substance) |
Inferred relationship |
Some |
1 |
| Product containing tobramycin in ocular dose form (medicinal product form) |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
True |
Tobramycin (substance) |
Inferred relationship |
Some |
1 |
| Product containing tobramycin in pulmonary dose form (medicinal product form) |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
True |
Tobramycin (substance) |
Inferred relationship |
Some |
1 |
| Dexamethasone- and tobramycin-containing product in ocular dose form |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
True |
Tobramycin (substance) |
Inferred relationship |
Some |
2 |
| Dexamethasone and tobramycin only product |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
True |
Tobramycin (substance) |
Inferred relationship |
Some |
2 |
| Loteprednol and tobramycin only product |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
True |
Tobramycin (substance) |
Inferred relationship |
Some |
1 |
| Product containing only fluorometholone and tobramycin (medicinal product) |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
True |
Tobramycin (substance) |
Inferred relationship |
Some |
2 |
| Product containing only tobramycin (medicinal product) |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
True |
Tobramycin (substance) |
Inferred relationship |
Some |
1 |
| Tobramycin only product in parenteral dose form |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
True |
Tobramycin (substance) |
Inferred relationship |
Some |
1 |
| Tobramycin only product in ocular dose form |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
True |
Tobramycin (substance) |
Inferred relationship |
Some |
1 |
| Product containing only tobramycin in pulmonary dose form (medicinal product form) |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
True |
Tobramycin (substance) |
Inferred relationship |
Some |
1 |
| Dexamethasone and tobramycin only product in ocular dose form |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
True |
Tobramycin (substance) |
Inferred relationship |
Some |
2 |
| Product containing precisely tobramycin (as tobramycin sulfate) 40 milligram/1 milliliter conventional release solution for injection (clinical drug) |
This attribute represents an ingredient that is the part of the active ingredient that the strength of a given product is based upon. |
True |
Tobramycin (substance) |
Inferred relationship |
Some |
1 |
| Tobramycin 3 mg/mL eye solution |
The most specific description of a substance present in the manufactured dose form, before any dilution or transformation. It includes modifiers, such as salts, esters, polymers (e.g. pegylation), and/or solvates (including waters of hydration). |
True |
Tobramycin (substance) |
Inferred relationship |
Some |
1 |
| Tobramycin 3 mg/mL eye solution |
This attribute represents an ingredient that is the part of the active ingredient that the strength of a given product is based upon. |
True |
Tobramycin (substance) |
Inferred relationship |
Some |
1 |
| Tobramycin 3 mg/g eye ointment |
The most specific description of a substance present in the manufactured dose form, before any dilution or transformation. It includes modifiers, such as salts, esters, polymers (e.g. pegylation), and/or solvates (including waters of hydration). |
True |
Tobramycin (substance) |
Inferred relationship |
Some |
1 |
| Tobramycin 3 mg/g eye ointment |
This attribute represents an ingredient that is the part of the active ingredient that the strength of a given product is based upon. |
True |
Tobramycin (substance) |
Inferred relationship |
Some |
1 |
| Dexamethasone 500 microgram/mL and tobramycin 3 mg/mL eye suspension |
The most specific description of a substance present in the manufactured dose form, before any dilution or transformation. It includes modifiers, such as salts, esters, polymers (e.g. pegylation), and/or solvates (including waters of hydration). |
True |
Tobramycin (substance) |
Inferred relationship |
Some |
2 |
| Dexamethasone 500 microgram/mL and tobramycin 3 mg/mL eye suspension |
This attribute represents an ingredient that is the part of the active ingredient that the strength of a given product is based upon. |
True |
Tobramycin (substance) |
Inferred relationship |
Some |
2 |
| Product containing precisely tobramycin 60 milligram/1 milliliter conventional release solution for inhalation (clinical drug) |
This attribute represents an ingredient that is the part of the active ingredient that the strength of a given product is based upon. |
False |
Tobramycin (substance) |
Inferred relationship |
Some |
1 |
| Product containing precisely tobramycin 60 milligram/1 milliliter conventional release solution for inhalation (clinical drug) |
The most specific description of a substance present in the manufactured dose form, before any dilution or transformation. It includes modifiers, such as salts, esters, polymers (e.g. pegylation), and/or solvates (including waters of hydration). |
False |
Tobramycin (substance) |
Inferred relationship |
Some |
1 |
| Product containing precisely fluorometholone acetate 1 milligram/1 milliliter and tobramycin 3 milligram/1 milliliter conventional release eye suspension (clinical drug) |
This attribute represents an ingredient that is the part of the active ingredient that the strength of a given product is based upon. |
True |
Tobramycin (substance) |
Inferred relationship |
Some |
1 |
| Product containing precisely fluorometholone acetate 1 milligram/1 milliliter and tobramycin 3 milligram/1 milliliter conventional release eye suspension (clinical drug) |
The most specific description of a substance present in the manufactured dose form, before any dilution or transformation. It includes modifiers, such as salts, esters, polymers (e.g. pegylation), and/or solvates (including waters of hydration). |
True |
Tobramycin (substance) |
Inferred relationship |
Some |
1 |
| Tobramycin (as tobramycin sulfate) 1.2 g powder for solution for injection vial |
This attribute represents an ingredient that is the part of the active ingredient that the strength of a given product is based upon. |
True |
Tobramycin (substance) |
Inferred relationship |
Some |
1 |
| Loteprednol etabonate 5 mg/mL and tobramycin 3 mg/mL eye suspension |
The most specific description of a substance present in the manufactured dose form, before any dilution or transformation. It includes modifiers, such as salts, esters, polymers (e.g. pegylation), and/or solvates (including waters of hydration). |
True |
Tobramycin (substance) |
Inferred relationship |
Some |
1 |
| Loteprednol etabonate 5 mg/mL and tobramycin 3 mg/mL eye suspension |
This attribute represents an ingredient that is the part of the active ingredient that the strength of a given product is based upon. |
True |
Tobramycin (substance) |
Inferred relationship |
Some |
1 |
| Fluorometholone and tobramycin only product in ocular dose form |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
True |
Tobramycin (substance) |
Inferred relationship |
Some |
2 |
| Loteprednol and tobramycin only product in ocular dose form |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
True |
Tobramycin (substance) |
Inferred relationship |
Some |
1 |
| Product containing fluorometholone and tobramycin in ocular dose form (medicinal product form) |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
True |
Tobramycin (substance) |
Inferred relationship |
Some |
2 |
| Product containing loteprednol and tobramycin in ocular dose form (medicinal product form) |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
True |
Tobramycin (substance) |
Inferred relationship |
Some |
1 |
| Dexamethasone 1 mg/mL and tobramycin 3 mg/mL eye drops |
The most specific description of a substance present in the manufactured dose form, before any dilution or transformation. It includes modifiers, such as salts, esters, polymers (e.g. pegylation), and/or solvates (including waters of hydration). |
True |
Tobramycin (substance) |
Inferred relationship |
Some |
2 |
| Dexamethasone 1 mg/mL and tobramycin 3 mg/mL eye drops |
This attribute represents an ingredient that is the part of the active ingredient that the strength of a given product is based upon. |
True |
Tobramycin (substance) |
Inferred relationship |
Some |
2 |
| Product containing precisely dexamethasone phosphate (as dexamethasone sodium phosphate) 1 milligram/1 milliliter and tobramycin (as tobramycin sulfate) 3 milligram/1 milliliter conventional release eye drops (clinical drug) |
This attribute represents an ingredient that is the part of the active ingredient that the strength of a given product is based upon. |
True |
Tobramycin (substance) |
Inferred relationship |
Some |
1 |
| Product containing precisely tobramycin 40 milligram/1 milliliter conventional release solution for injection (clinical drug) |
The most specific description of a substance present in the manufactured dose form, before any dilution or transformation. It includes modifiers, such as salts, esters, polymers (e.g. pegylation), and/or solvates (including waters of hydration). |
True |
Tobramycin (substance) |
Inferred relationship |
Some |
1 |
| Product containing precisely tobramycin 40 milligram/1 milliliter conventional release solution for injection (clinical drug) |
This attribute represents an ingredient that is the part of the active ingredient that the strength of a given product is based upon. |
True |
Tobramycin (substance) |
Inferred relationship |
Some |
1 |
| Tobramycin 28 mg/actuation powder for inhalation |
The most specific description of a substance present in the manufactured dose form, before any dilution or transformation. It includes modifiers, such as salts, esters, polymers (e.g. pegylation), and/or solvates (including waters of hydration). |
True |
Tobramycin (substance) |
Inferred relationship |
Some |
1 |
| Tobramycin 28 mg/actuation powder for inhalation |
This attribute represents an ingredient that is the part of the active ingredient that the strength of a given product is based upon. |
True |
Tobramycin (substance) |
Inferred relationship |
Some |
1 |
| Product containing precisely tobramycin 60 milligram/1 milliliter conventional release solution for nebulizer (clinical drug) |
The most specific description of a substance present in the manufactured dose form, before any dilution or transformation. It includes modifiers, such as salts, esters, polymers (e.g. pegylation), and/or solvates (including waters of hydration). |
True |
Tobramycin (substance) |
Inferred relationship |
Some |
1 |
| Product containing precisely tobramycin 60 milligram/1 milliliter conventional release solution for nebulizer (clinical drug) |
This attribute represents an ingredient that is the part of the active ingredient that the strength of a given product is based upon. |
True |
Tobramycin (substance) |
Inferred relationship |
Some |
1 |
| Serum tobramycin measurement |
Component |
True |
Tobramycin (substance) |
Inferred relationship |
Some |
1 |
| Plasma tobramycin measurement |
Component |
True |
Tobramycin (substance) |
Inferred relationship |
Some |
1 |
FHIR
© HL7.org
|
Server Home |
FHIR Server FHIR Server 3.7.22-SNAPSHOT
|
FHIR Version n/a
User: [n/a]